JUBILANT INGREVIA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 518.5 INR | -1.44% |
|
+1.35% | +1.95% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 41.36B 497M | Sales 2025 * | 47.73B 573M | Capitalization | 84.38B 1.01B |
|---|---|---|---|---|---|
| Net income 2024 | 1.83B 21.97M | Net income 2025 * | 2.67B 32.05M | EV / Sales 2024 | 1.74 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 |
39.2
x | P/E ratio 2025 * |
31.5
x | Employees | 2,295 |
| Yield 2024 * |
0.76% | Yield 2025 * |
0.73% | Free-Float | 42.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Jubilant Ingrevia Limited
| 1 day | -1.44% | ||
| 1 week | +1.35% | ||
| Current month | -6.24% | ||
| 1 month | -4.04% | ||
| 3 months | +6.87% | ||
| 6 months | +22.55% | ||
| Current year | +1.95% |
1 week
500.00
562.25
1 month
500.00581.70
Current year
420.00581.70
1 year
379.05581.70
3 years
350.45838.75
5 years
241.30838.75
10 years
241.30838.75
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Jain
CEO | Chief Executive Officer | - | 23-09-30 |
| Chief Executive Officer | 60 | 98-07-12 | |
| Director of Finance/CFO | 35 | 21-02-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 21-02-05 | |
| Chairman | 71 | 21-02-05 | |
| Director/Board Member | 46 | 21-02-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 112 M€ | +5.31% | - | |
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 518.5 | -1.44% | 166 538 |
| 24-05-18 | 529.8 | +0.69% | 38,482 |
| 24-05-17 | 526.1 | -2.32% | 224,030 |
| 24-05-16 | 538.6 | -1.80% | 321,637 |
| 24-05-15 | 548.5 | +7.21% | 2,717,844 |
Delayed Quote NSE India S.E., May 21, 2024 at 04:27 am EDT
More quotes
Jubilant Ingrevia Limited is an India-based integrated provider of life sciences products and solutions. The Company's segments include Speciality Chemicals, Nutrition and Health Solutions, and Chemical Intermediates. The Speciality Chemicals segment includes pyridine and picolines, fine chemicals, agro chemicals, and custom development and manufacturing organization. The Nutrition and Health Solutions segment includes nutrition and health ingredients, and animal and human nutrition health solutions. The Chemical Intermediates segment includes acetyls and speciality ethanol. Its agro chemicals business is focused on agro intermediates and agro actives, including insecticides, herbicides and fungicides. Its range of products includes nutritional ingredients, such as vitamin B3, vitamin B4, picolinates and premix formulations for both animal and human nutrition. The Company serves various industries, such as pharmaceutical, nutrition, agrochemical, consumer and industrial customers.
Sector
Specialty Chemicals
Calendar
2024-07-15
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
529.8
INR
Average target price
567
INR
Spread / Average Target
+7.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.95% | 1.01B | |
| +3.65% | 49.69B | |
| +20.15% | 42.41B | |
| +23.39% | 26.65B | |
| +13.29% | 19.62B | |
| +0.75% | 17.1B | |
| -24.51% | 15.43B | |
| +3.67% | 15.64B | |
| -9.92% | 15.3B | |
| -18.80% | 13.97B |
- Stock Market
- Equities
- JUBLINGREA Stock